Patents

Magnetic Therapy to Prevent Recurring Heart Attack

Magnetic Therapy Could Prevent Recurrent Heart Attack

This dissertation deals with the problem of improving the effectiveness of thrombolytic therapy in patients with acute myocardial infarction. In this research, archival case records of 94 patients are analyzed comparative efficiency of most applied in Ukraine of the thrombolytic therapy - Alteplase and Streptokinase and justified their advantage, taking into the account of long-term results.

There were determined particularities of clinical course of acute myocardial infarction, terms and duration of hypercoagulative syndrome after result of survey of 80 in-patients with the thrombolysis and heparin therapy, mechanisms and variants of violations of hemostasis are biochemically specified.

There were grounded expediences of application of magnetic therapy as hypocoagulative method, which can improve clinical course of acute myocardial infarction and prevent coronary re-thrombosis.

There is determined that at the patients with acute myocardial infarction after TLT and heparin therapy in the case of hemostasis violations to the hypercoagulability is expedient in the complex of medical measures the daily sessions of magnetic therapy (inductance of alternating current of 20 mTl on the heart area and inductance of sinusoidal current of 14 mTl on the liver area) with exposition about 20 minutes within 10 days for activating of the anticoagulant system and fibrinolysis activating

. In this work it has been justified that magnetic therapy application after TLT at time of heparin thereby stopping takes positive effect in diminishing of biochemical signs of hypercoagulability and prevents the developing of recurrent myocardial infarction.

It compares the effectiveness of the commonly used thrombolytics (alteplase and streptokinase) and justified their advantage, taking into the account of long-term results. According to the survey result of 80 in patients especially during myocardial infarction and after received TLT and heparin therapy, it has clinically established the profile of time frame of formation and duration of preservation hypercoagulability syndrome, biochemical mechanisms of specific breaches of hemostasis.

In this work it has been justified the application of magnetic therapy feasibility for hypocoagulation that can improve the clinical condition of disease and preventivemeasure of rethrombosis.

Patent

P.K. Panigrahi, N.A.Zolotaryova.Ukraine Patent: No: 36504 . IPC A61N2/00.”Method for prevention and treatment of myocardial infarction” .// the applicant and patent-holder

No.u 200807405:application of 29.05.08: published on 27.10.2008. Bulletin No.20.